RESUMEN
Dientamoeba fragilis is a common enteropathogen of humans. Recently a cyst stage of the parasite was described in an animal model; however, no cyst stage has been described in detail from clinical samples. We describe both cyst and precystic forms from human clinical samples.
Asunto(s)
Dientamoeba/citología , Dientamebiasis/parasitología , Esporas Protozoarias/citología , Dientamoeba/fisiología , Humanos , Microscopía , Esporas Protozoarias/fisiologíaRESUMEN
Dientamoeba fragilis is an inhabitant of the human bowel and is associated with gastrointestinal illness. Despite its discovery over a century ago, the details of Dientamoeba's life cycle are unclear and its mode of transmission is unknown. Several theories exist which attempt to explain how Dientamoeba may be transmitted. One theory suggests that animals are responsible for the transmission of Dientamoeba. However, reports of Dientamoeba in animals are sporadic and most are not supported by molecular evidence. Another theory suggests that Dientamoeba may be transmitted via the ova of a helminth. Given that the closest relative of Dientamoeba is transmitted via the ova of a helminth, this theory seems plausible. It has also been suggested that Dientamoeba could be transmitted directly between humans. This theory also seems plausible given that other relatives of Dientamoeba are transmitted in this way. Despite numerous investigations, Dientamoeba's mode of transmission remains unknown. This review discusses the strengths and weaknesses of theories relating to Dientamoeba's mode of transmission and, by doing so, indicates where gaps in current knowledge exist. Where information is lacking, suggestions are made as to how future research could improve our knowledge on the life cycle of Dientamoeba.
Asunto(s)
Dientamoeba/fisiología , Dientamebiasis/transmisión , Animales , Dientamoeba/clasificación , Dientamoeba/patogenicidad , Dientamebiasis/parasitología , Enterobius/parasitología , Heces/parasitología , Humanos , Estadios del Ciclo de Vida , Óvulo/parasitología , Trichomonadida/clasificación , Trichomonadida/patogenicidad , Trichomonadida/fisiologíaRESUMEN
Dientamoeba fragilis is a pathogenic protozoan parasite that is implicated as a cause of human diarrhoea. A case-controlled study was conducted to determine the clinical signs associated with D. fragilis infection in children presenting to a Sydney Hospital. Treatment options are also discussed. Stool specimens were collected from children aged 15 years or younger and analysed for the presence of D. fragilis. In total, 41 children were included in the study along with a control group. Laboratory diagnosis was performed by microscopy of permanently stained, fixed faecal smears and by real-time PCR. Gastrointestinal symptoms were present in 40/41 (98%) of these children with dientamoebiasis, with diarrhoea (71%) and abdominal pain (29%) the most common clinical signs. Chronic gastrointestinal symptoms were present in 2% of cases. The most common anti-microbial used for treatment was metronidazole (n=41), with complete resolution of symptoms and clearance of parasite occurring in 85% of cases. A treatment failure rate occurred in 15% of those treated with metronidazole. Follow-up treatment comprised of an additional course of metronidazole or iodoquinol was needed in order to achieve complete resolution of infection and symptoms in this group. This study demonstrates the pathogenic potential of D. fragilis in children and as such it is recommended that all laboratories must routinely test for this organism and treat if detected.
Asunto(s)
Dientamebiasis/diagnóstico , Dientamebiasis/tratamiento farmacológico , Metronidazol/uso terapéutico , Dolor Abdominal/etiología , Adolescente , Antiprotozoarios/uso terapéutico , Australia/epidemiología , Estudios de Casos y Controles , Niño , Preescolar , Diarrea/etiología , Dientamoeba/fisiología , Dientamebiasis/complicaciones , Dientamebiasis/epidemiología , Dientamebiasis/patología , Heces/parasitología , Femenino , Humanos , Lactante , Yodoquinol/uso terapéutico , Masculino , Resultado del TratamientoRESUMEN
INTRODUCTION: The clinical significance of Blastocystis sp. and Dientamoeba fragilis in patients with gastrointestinal symptoms is a controversial issue. Since the pathogenicity of these protists has not been fully elucidated, testing for these organisms is not routinely pursued by most laboratories and clinicians. Thus, the prevalence of these organisms and the subtypes of Blastocystis sp. in human patients in Turkey are not well characterized. This study aimed to determine the prevalence of Blastocystis sp. and D. fragilis in the diarrheic stool samples of immunodeficient and immunocompetent patients using conventional and molecular methods and to identify Blastocystis sp. subtypes using next generation sequencing. MATERIAL AND METHODS: Individual stool specimens were collected from 245 immunodeficient and 193 immunocompetent diarrheic patients between March 2017 and December 2019 at the Gazi University Training and Research Hospital in Ankara, Turkey. Samples were screened for Blastocystis sp. and D. fragilis by conventional and molecular methods. Molecular detection of both protists was achieved by separate qPCRs targeting a partial fragment of the SSU rRNA gene. Next generation sequencing was used to identify Blastocystis sp. subtypes. RESULTS: The prevalence of Blastocystis sp. and D. fragilis was 16.7% and 11.9%, respectively as measured by qPCR. The prevalence of Blastocystis sp. and D. fragilis was lower in immunodeficient patients (12.7% and 10.6%, respectively) compared to immunocompetent patients (21.8% and 13.5%, respectively). Five Blastocystis sp. subtypes were identified and the following subtype distribution was observed: ST3 54.4% (n = 37), ST2 16.2% (n = 11), ST1 4.4% (n = 3), ST6 2.9% (n = 2), ST4 1.5% (n = 1), ST2/ST3 11.8% (n = 8) and ST1/ST3 8.8% (n = 6). There was no statistically significant difference in the distribution of Blastocystis sp. subtypes between immunocompetent and immunodeficient patients. CONCLUSION AND RECOMMENDATION: Our findings demonstrated that Blastocystis sp. and D. fragilis are commonly present in immunocompetent and immunodeficient patients with diarrhea. This study is the first to use next generation sequencing to address the presence of Blastocystis sp. mixed subtypes and intra-subtype variability in clinical samples in Turkey.
Asunto(s)
Blastocystis/aislamiento & purificación , Diarrea/parasitología , Dientamoeba/aislamiento & purificación , Enfermedades de Inmunodeficiencia Primaria/parasitología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Blastocystis/genética , Blastocystis/fisiología , Diarrea/inmunología , Dientamoeba/genética , Dientamoeba/fisiología , Heces/parasitología , Femenino , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Inmunocompetencia , Masculino , Persona de Mediana Edad , Enfermedades de Inmunodeficiencia Primaria/inmunología , Turquía , Adulto JovenRESUMEN
Dientamoeba fragilis is an intestinal protozoan, an inhabitant of the human gastrointestinal tract, with a worldwide distribution. The reported prevalence of D. fragilis varies worldwide in different populations between 0.3% and 82.9%, and its role as a pathogen is still unclear. The parasite has been identified in the faeces of asymptomatic patients and with different acute and chronic symptoms, like abdominal pain, diarrhoea, flatulence, nausea and vomiting. The aims of this study were to evaluate the prevalence of D. fragilis in the North-East of Italy, and the clinical improvement of symptoms after recommended treatment with paromomycin or metronidazole. Furthermore, a literature review of D. fragilis prevalence studies in Italy was carried out to show the Italian situation. Of 575 enrolled people, 85 (14.8%) were positive for D. fragilis. The most prevalent symptoms were abdominal pain 28.2%, anal itching 27.1%, watery diarrhoea 18.8%, meteorism 16.5% and nausea/lack of appetite 14.1%. The high rate of anal itching was unexpected, because it wasn't a common symptom. 32 patients were co-infected with B. hominis (37.7%) and three with G. lamblia (3.5%). Our study showed paromomycin had a high efficacy for treatment of D. fragilis infections 100.0% (45/45), while caution must be used when using metronidazole 53.3% (24/40). We recommend paromomycin for empirical treatment, given its great effectiveness in our population.
Asunto(s)
Antiprotozoarios/farmacología , Dientamoeba/aislamiento & purificación , Dientamebiasis/epidemiología , Metronidazol/farmacología , Paromomicina/farmacología , Adolescente , Adulto , Anciano , Niño , Preescolar , Estudios Transversales , Dientamoeba/fisiología , Dientamebiasis/parasitología , Dientamebiasis/prevención & control , Femenino , Humanos , Lactante , Italia/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Adulto JovenRESUMEN
The role of Enterobius vermicularis in the transmission of Dientamoeba fragilis has been evaluated in two groups of patients admitted to the Parasitology Laboratory of Celal Bayar University: one group with E. vermicularis infection (n=187, Pinworm Group), and the other with D. fragilis infection (n=126, Dientamoeba Group). The presence of the other parasite, pinworm or Dientamoeba, was investigated with the microscopic examination of cellophane tape and stool samples for three consecutive days. In the Pinworm Group, 9.6% of the patients were found to be coinfected with D. fragilis, while 25.4% of the patients in the Dientamoeba Group were found to be coinfected with pinworms. The coincidence rates of D. fragilis and E. vermicularis, higher than the prevalence of each parasite in similar populations, suggest a common relation between these two parasites, possibly in entering the human body. E. vermicularis infection was found to be significantly more common in younger children (p<0.001), indicating that younger children may also be at higher risk for D. fragilis infection. These findings also raise the question of whether the unrelated symptoms of the pinworm infected patients such as abdominal pain and diarrhea may actually be due to overlooked Dientamoeba infections.
Asunto(s)
Dientamoeba , Dientamebiasis/epidemiología , Enterobiasis/epidemiología , Enterobius , Parasitosis Intestinales/epidemiología , Adolescente , Adulto , Anciano , Animales , Niño , Preescolar , Dientamoeba/fisiología , Dientamebiasis/complicaciones , Dientamebiasis/parasitología , Dientamebiasis/transmisión , Vectores de Enfermedades , Enterobiasis/complicaciones , Enterobiasis/parasitología , Enterobius/fisiología , Heces/parasitología , Femenino , Humanos , Parasitosis Intestinales/parasitología , Parasitosis Intestinales/transmisión , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Recto/parasitologíaRESUMEN
The development and integration of DNA-based methods in research and clinical microbiology laboratories have enabled standardised and comprehensive detection and differentiation of the microbes colonising our guts. For instance, the single-celled parasites Blastocystis and Dientamoeba appear to be much more common than previously thought, especially so in healthy individuals. While increasing evidence appears to suggest limited pathogenicity of these parasites, next-generation-sequencing-based studies have helped us to appreciate links between parasite colonisation and certain host phenotypical characteristics and gut microbial profiles. The fundamental question remains as to whether such parasites are merely indicators or active manipulators of gut microbiota structure and function. In this article, we collate existing evidence that these parasites are, at minimum, indicators of intestinal microbiota structure.
Asunto(s)
Blastocystis/fisiología , Dientamoeba/fisiología , Biomarcadores Ambientales , Microbioma Gastrointestinal/fisiología , Interacciones Huésped-Parásitos/fisiología , Parasitosis Intestinales/microbiología , Humanos , Intestinos/microbiología , Intestinos/parasitologíaRESUMEN
OBJECTIVES: Dientamoeba fragilis is a pathogenic protozoan of the human gastrointestinal tract with a worldwide distribution, which has emerged as an important and misdiagnosed cause of chronic gastrointestinal illnesses such as diarrhea and 'irritable-bowel-like' gastrointestinal disease. Very little research has been conducted on the use of suitable antimicrobial compounds. Furthermore, higher rates of co-infection with Enterobius vermicularis have been described, suggesting that E. vermicularis could influence the treatment of D. fragilis-infected patients. To study this, the treatment of E. vermicularis and D. fragilis co-infected patients was evaluated. METHODS: Forty-nine patients with a D. fragilis infection, including 25 (51.0%) patients co-infected with E. vermicularis, were studied. All of them were treated with metronidazole. Patients with E. vermicularis co-infection and/or an E. vermicularis-positive case in the family were treated with mebendazole. RESULTS: Metronidazole treatment failure was significantly more frequent in patients with E. vermicularis co-infection and in patients with children in the family. CONCLUSIONS: Co-infection with E. vermicularis may act as a factor favoring D. fragilis infection by preventing eradication measures. This suggests that both parasites should be treated simultaneously.
Asunto(s)
Coinfección/tratamiento farmacológico , Dientamoeba/efectos de los fármacos , Dientamebiasis/tratamiento farmacológico , Enterobiasis/tratamiento farmacológico , Enterobius/efectos de los fármacos , Adolescente , Adulto , Anciano , Animales , Antihelmínticos/administración & dosificación , Antiprotozoarios , Niño , Preescolar , Coinfección/parasitología , Dientamoeba/fisiología , Dientamebiasis/parasitología , Enterobiasis/parasitología , Enterobius/parasitología , Heces/parasitología , Femenino , Humanos , Masculino , Mebendazol/administración & dosificación , Metronidazol/administración & dosificación , Persona de Mediana Edad , Adulto JovenRESUMEN
Dientamoeba fragilis is a protozoan parasite emerging as a cause of diarrhoea and "irritable-bowel-like" gastrointestinal disease in humans with a propensity for establishing long-term, chronic infections in humans. Although Dientamoeba was discovered over a century ago its life cycle and mode of transmission is not known. No cyst stage has been described and no animal models are presently available for the study of this parasite. Here we describe the establishment of an animal model using laboratory rodents, the fulfilling of Koch's postulates, and the discovery of a new cyst stage in the life cycle of D. fragilis. Our demonstration of long-term parasite carriage by rodents and prolonged shedding of cysts, together with elevated levels of calprotectin in the stool, confirms the capacity of this organism to cause disease and indicates dientamoebiasis should be considered in the differential diagnosis of gastrointestinal diseases such as Inflammatory Bowel Syndrome (IBS). Finally, we suggest that the cyst stage described here is the vehicle that mediates faecal-oral transmission of D. fragilis between hosts.
Asunto(s)
Dientamoeba/fisiología , Dientamebiasis/parasitología , Estadios del Ciclo de Vida , Esporas Protozoarias/fisiología , Animales , Dientamebiasis/transmisión , Modelos Animales de Enfermedad , Heces/parasitología , Humanos , Parasitosis Intestinales/parasitología , Parasitosis Intestinales/transmisión , RoedoresRESUMEN
Ever since its first description in 1918, Dientamoeba fragilis has struggled to gain recognition as a significant pathogen. There is little justification for this neglect, however, since there exists a growing body of case reports from numerous countries around the world that have linked this protozoal parasite to clinical manifestations such as diarrhea, abdominal pain, flatulence, and anorexia. A number of studies have even incriminated D. fragilis as a cause of irritable bowel syndrome, allergic colitis, and diarrhea in human immunodeficiency virus patients. Although D. fragilis is most commonly identified using permanently stained fecal smears, recent advances in culturing techniques are simplifying as well as improving the ability of investigators to detect this organism. However, there are limitations in the use of cultures since they cannot be performed on fecal samples that have been fixed. Significant progress has been made in the biological classification of this organism, which originally was described as an ameba. Analyses of small-subunit rRNA gene sequences have clearly demonstrated its close relationship to Histomonas, and it is now known to be a trichomonad. How the organism is transmitted remains a mystery, although there is some evidence that D. fragilis might be transmitted via the ova of the pinworm, Enterobius vermicularis. Also, it remains to be answered whether the two distinct genotypes of D. fragilis recently identified represent organisms with differing virulence.